164 related articles for article (PubMed ID: 27620481)
1. In Vitro Activity of Solithromycin against Bordetella pertussis, an Emerging Respiratory Pathogen.
Hardy DJ; Vicino D; Fernandes P
Antimicrob Agents Chemother; 2016 Dec; 60(12):7043-7045. PubMed ID: 27620481
[TBL] [Abstract][Full Text] [Related]
2. In vitro activity and clinical efficacy of macrolides, cefoperazone-sulbactam and piperacillin/piperacillin-tazobactam against Bordetella pertussis and the clinical manifestations in pertussis patients due to these isolates: A single-centre study in Zhejiang Province, China.
Hua CZ; Wang HJ; Zhang Z; Tao XF; Li JP; Mi YM; Tang LF; Chen ZM
J Glob Antimicrob Resist; 2019 Sep; 18():47-51. PubMed ID: 30710647
[TBL] [Abstract][Full Text] [Related]
3. Solithromycin: A Novel Fluoroketolide for the Treatment of Community-Acquired Bacterial Pneumonia.
Zhanel GG; Hartel E; Adam H; Zelenitsky S; Zhanel MA; Golden A; Schweizer F; Gorityala B; Lagacé-Wiens PR; Walkty AJ; Gin AS; Hoban DJ; Lynch JP; Karlowsky JA
Drugs; 2016 Dec; 76(18):1737-1757. PubMed ID: 27909995
[TBL] [Abstract][Full Text] [Related]
4. Results from the Solithromycin International Surveillance Program (2014).
Farrell DJ; Flamm RK; Sader HS; Jones RN
Antimicrob Agents Chemother; 2016 Jun; 60(6):3662-8. PubMed ID: 27044551
[TBL] [Abstract][Full Text] [Related]
5. [Susceptibility to macrolide antibiotics of Bordetella pertussis and Bordetella parapertussis strains isolated from whooping cough patients in 1968 and in 1997-99].
Chodorowska M; Kuklińska D; Tyski S
Med Dosw Mikrobiol; 2001; 53(1):39-43. PubMed ID: 11757403
[TBL] [Abstract][Full Text] [Related]
6. In vitro activity of solithromycin and its metabolites, CEM-214 and N-acetyl-CEM-101, against 100 clinical Ureaplasma spp. isolates compared with azithromycin.
Furfaro LL; Spiller OB; Keelan JA; Payne MS
Int J Antimicrob Agents; 2015 Sep; 46(3):319-24. PubMed ID: 26141231
[TBL] [Abstract][Full Text] [Related]
7. Bordetella pertussis Infection in Infants and Young Children in Shanghai, China, 2016-2017: Clinical Features, Genotype Variations of Antigenic Genes and Macrolides Resistance.
Fu P; Wang C; Tian H; Kang Z; Zeng M
Pediatr Infect Dis J; 2019 Apr; 38(4):370-376. PubMed ID: 30882726
[TBL] [Abstract][Full Text] [Related]
8. Antimicrobial activity of solithromycin against serotyped macrolide-resistant Streptococcus pneumoniae isolates collected from U.S. medical centers in 2012.
Farrell DJ; Mendes RE; Jones RN
Antimicrob Agents Chemother; 2015 Apr; 59(4):2432-4. PubMed ID: 25605359
[TBL] [Abstract][Full Text] [Related]
9. The solithromycin journey-It is all in the chemistry.
Fernandes P; Martens E; Bertrand D; Pereira D
Bioorg Med Chem; 2016 Dec; 24(24):6420-6428. PubMed ID: 27595539
[TBL] [Abstract][Full Text] [Related]
10. Surveillance of the activity of solithromycin (CEM-101) against bacteria from respiratory tract infections.
Hawser S; Morrissey I; Lemos B; Keedy K; Fernandes P
Int J Antimicrob Agents; 2017 Jul; 50(1):17-22. PubMed ID: 28483717
[TBL] [Abstract][Full Text] [Related]
11. In vitro activity of macrolides against Bordetella pertussis strains isolated in 1968 and 30 years later in Poland.
Chodorowska M; Tyski S; Kuklińska D
Clin Microbiol Infect; 2000 Jan; 6(1):50-2. PubMed ID: 11168039
[No Abstract] [Full Text] [Related]
12. Antimicrobial susceptibility testing of Finnish Bordetella pertussis isolates collected during 2006-2017.
Lönnqvist E; Barkoff AM; Mertsola J; He Q
J Glob Antimicrob Resist; 2018 Sep; 14():12-16. PubMed ID: 29486357
[TBL] [Abstract][Full Text] [Related]
13. Spotlight on solithromycin in the treatment of community-acquired bacterial pneumonia: design, development, and potential place in therapy.
Donald BJ; Surani S; Deol HS; Mbadugha UJ; Udeani G
Drug Des Devel Ther; 2017; 11():3559-3566. PubMed ID: 29263651
[TBL] [Abstract][Full Text] [Related]
14. Antimicrobial activity of solithromycin and levofloxacin against a murine pneumonia mixed-infection model caused by Streptococcus pneumoniae and anaerobic bacteria.
Kato H; Yamagishi Y; Hagihara M; Yokoyama Y; Suematsu H; Asai N; Koizumi Y; Mikamo H
J Infect Chemother; 2019 Apr; 25(4):311-313. PubMed ID: 30287186
[TBL] [Abstract][Full Text] [Related]
15. In-vitro activity of solithromycin against anaerobic bacteria from the normal intestinal microbiota.
Weintraub A; Rashid MU; Nord CE
Anaerobe; 2016 Dec; 42():119-122. PubMed ID: 27725229
[TBL] [Abstract][Full Text] [Related]
16. Where macrolide resistance is prevalent.
Li Y; Liu X; Zhang B; He Q; Wang Z
APMIS; 2015 Apr; 123(4):361-3. PubMed ID: 25703275
[No Abstract] [Full Text] [Related]
17. The First Report of Macrolide-Resistant Bordetella pertussis Isolation in Japan.
Yamaguchi T; Kawasaki Y; Katsukawa C; Kawahara R; Kawatsu K
Jpn J Infect Dis; 2020 Sep; 73(5):361-362. PubMed ID: 32350216
[TBL] [Abstract][Full Text] [Related]
18. Clinical manifestations of children with microbiologically confirmed pertussis infection and antimicrobial susceptibility of isolated strains in a regional hospital in Japan, 2008-2012.
Horiba K; Nishimura N; Gotoh K; Kawaguchi M; Takeuchi S; Hattori F; Isaji M; Okai Y; Hosono H; Takemoto K; Ozaki T
Jpn J Infect Dis; 2014; 67(5):345-8. PubMed ID: 25241683
[TBL] [Abstract][Full Text] [Related]
19. Antimicrobial characterisation of solithromycin (CEM-101), a novel fluoroketolide: activity against staphylococci and enterococci.
Putnam SD; Sader HS; Farrell DJ; Biedenbach DJ; Castanheira M
Int J Antimicrob Agents; 2011 Jan; 37(1):39-45. PubMed ID: 21075602
[TBL] [Abstract][Full Text] [Related]
20. The in vitro evaluation of solithromycin (CEM-101) against pathogens isolated in the United States and Europe (2009).
Farrell DJ; Castanheira M; Sader HS; Jones RN
J Infect; 2010 Dec; 61(6):476-83. PubMed ID: 20831882
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
